Reference entry — not sold here. The intrigue: it's a fragment of the same hormone behind the tanning and libido peptides (α-MSH) — but it's the anti-inflammatory tail that does NOT act like a melanocortin at all. In the July 2026 FDA PCAC batch alongside BPC-157, TB-500 and MOTS-c. No dosing publis
KPV is the anti-inflammatory C-terminal tripeptide of α-MSH — the same hormone behind the melanotan and PT-141 peptides, but stripped of all melanocortin-receptor activity (no tanning, no appetite effect). It works intracellularly via the PepT1 transporter to block NF-κB, which makes it a gut/IBD-focused anti-inflammatory that can even be given orally. It has two decades of preclinical data (strongest in colitis models) but no human clinical trials, and it's currently under FDA compounding review (July 2026).
not approved.
Not FDA-approved. In the July 2026 PCAC review batch for 503A compounding (regulatory status in flux through the 2025–2026 review). Sold gray-market as a "research" peptide (often for gut health, sometimes alongside BPC-157).
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (FDA compounding status evolving — re-check the July PCAC outcome).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.